Cargando…
Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725505/ https://www.ncbi.nlm.nih.gov/pubmed/29250197 http://dx.doi.org/10.1007/s12254-017-0375-8 |
_version_ | 1783285538561720320 |
---|---|
author | Haidl, Friederike Pfister, David Heidenreich, Axel Heidegger, Isabel |
author_facet | Haidl, Friederike Pfister, David Heidenreich, Axel Heidegger, Isabel |
author_sort | Haidl, Friederike |
collection | PubMed |
description | The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year’s important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice. |
format | Online Article Text |
id | pubmed-5725505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-57255052017-12-14 Antiangiogenic therapies in urogenital malignancies: Fiction or fact? Haidl, Friederike Pfister, David Heidenreich, Axel Heidegger, Isabel Memo Review The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year’s important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice. Springer Vienna 2017-12-04 2017 /pmc/articles/PMC5725505/ /pubmed/29250197 http://dx.doi.org/10.1007/s12254-017-0375-8 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Haidl, Friederike Pfister, David Heidenreich, Axel Heidegger, Isabel Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
title | Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
title_full | Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
title_fullStr | Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
title_full_unstemmed | Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
title_short | Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
title_sort | antiangiogenic therapies in urogenital malignancies: fiction or fact? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725505/ https://www.ncbi.nlm.nih.gov/pubmed/29250197 http://dx.doi.org/10.1007/s12254-017-0375-8 |
work_keys_str_mv | AT haidlfriederike antiangiogenictherapiesinurogenitalmalignanciesfictionorfact AT pfisterdavid antiangiogenictherapiesinurogenitalmalignanciesfictionorfact AT heidenreichaxel antiangiogenictherapiesinurogenitalmalignanciesfictionorfact AT heideggerisabel antiangiogenictherapiesinurogenitalmalignanciesfictionorfact |